Cargando…

Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment

BACKGROUND & AIMS: Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Guerra, Manuel, González-Méndez, Yanira, de Molina, Patricia, Gimeno-García, Antonio Z., Carrillo, Marta, Casanova, Carlos, Pumarola, Tomás, Jimenez, Alejandro, Hernández-Porto, Miriam, Torres, Álvaro, Quintero, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493585/
https://www.ncbi.nlm.nih.gov/pubmed/23144908
http://dx.doi.org/10.1371/journal.pone.0048610
_version_ 1782249291631296512
author Hernández-Guerra, Manuel
González-Méndez, Yanira
de Molina, Patricia
Gimeno-García, Antonio Z.
Carrillo, Marta
Casanova, Carlos
Pumarola, Tomás
Jimenez, Alejandro
Hernández-Porto, Miriam
Torres, Álvaro
Quintero, Enrique
author_facet Hernández-Guerra, Manuel
González-Méndez, Yanira
de Molina, Patricia
Gimeno-García, Antonio Z.
Carrillo, Marta
Casanova, Carlos
Pumarola, Tomás
Jimenez, Alejandro
Hernández-Porto, Miriam
Torres, Álvaro
Quintero, Enrique
author_sort Hernández-Guerra, Manuel
collection PubMed
description BACKGROUND & AIMS: Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studies evaluating the immunogenicity, tolerance and acceptance of 2009 influenza A vaccine in CHC patients. METHODS: We evaluated the immunogenicity of influenza A vaccine (Pandemrix®) by using the hemagglutination inhibition (HI) titers method in a well defined cohort of CHC patients receiving or not receiving pegylated-interferon and ribavirin, and compared it with healthy subjects (controls). A group of patients with inflammatory bowel disease (IBD) under immunosuppression, thought to have a lower immune response to seasonal influenza vaccine, were also included as a negative control group. In addition, tolerance to injection site reactions and acceptance was assessed by a validated questionnaire (Vaccinees' perception of injection-VAPI-questionnaire). RESULTS: Of 114 subjects invited to participate, 68% accepted and, after exclusions, 72 were included. Post-vaccination geometric mean titers and seroprotection/seroconversion rates were optimal in CHC patients with ongoing treatment (n = 15; 232, CI95% 46–1166; 93%; 93%), without treatment (n = 10; 226, CI95% 69–743: 100%; 100%) and controls (n = 15;168, CI95% 42–680; 93%; 86%) with no differences between groups (P = 0.8). In contrast, IBD patients had a significantly lower immunogenic response (n = 27; 60, CI95% 42–680;66%;66%; P = 0.006). All the groups showed a satisfactory tolerance although CHC patients with ongoing treatment showed more local discomfort after vaccine injection. CONCLUSION: There appeared to be no differences between CHC patients and healthy controls in serological response and acceptance of (H1N1) influenza vaccination.
format Online
Article
Text
id pubmed-3493585
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34935852012-11-09 Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment Hernández-Guerra, Manuel González-Méndez, Yanira de Molina, Patricia Gimeno-García, Antonio Z. Carrillo, Marta Casanova, Carlos Pumarola, Tomás Jimenez, Alejandro Hernández-Porto, Miriam Torres, Álvaro Quintero, Enrique PLoS One Research Article BACKGROUND & AIMS: Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studies evaluating the immunogenicity, tolerance and acceptance of 2009 influenza A vaccine in CHC patients. METHODS: We evaluated the immunogenicity of influenza A vaccine (Pandemrix®) by using the hemagglutination inhibition (HI) titers method in a well defined cohort of CHC patients receiving or not receiving pegylated-interferon and ribavirin, and compared it with healthy subjects (controls). A group of patients with inflammatory bowel disease (IBD) under immunosuppression, thought to have a lower immune response to seasonal influenza vaccine, were also included as a negative control group. In addition, tolerance to injection site reactions and acceptance was assessed by a validated questionnaire (Vaccinees' perception of injection-VAPI-questionnaire). RESULTS: Of 114 subjects invited to participate, 68% accepted and, after exclusions, 72 were included. Post-vaccination geometric mean titers and seroprotection/seroconversion rates were optimal in CHC patients with ongoing treatment (n = 15; 232, CI95% 46–1166; 93%; 93%), without treatment (n = 10; 226, CI95% 69–743: 100%; 100%) and controls (n = 15;168, CI95% 42–680; 93%; 86%) with no differences between groups (P = 0.8). In contrast, IBD patients had a significantly lower immunogenic response (n = 27; 60, CI95% 42–680;66%;66%; P = 0.006). All the groups showed a satisfactory tolerance although CHC patients with ongoing treatment showed more local discomfort after vaccine injection. CONCLUSION: There appeared to be no differences between CHC patients and healthy controls in serological response and acceptance of (H1N1) influenza vaccination. Public Library of Science 2012-11-08 /pmc/articles/PMC3493585/ /pubmed/23144908 http://dx.doi.org/10.1371/journal.pone.0048610 Text en © 2012 Hernández-Guerra et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hernández-Guerra, Manuel
González-Méndez, Yanira
de Molina, Patricia
Gimeno-García, Antonio Z.
Carrillo, Marta
Casanova, Carlos
Pumarola, Tomás
Jimenez, Alejandro
Hernández-Porto, Miriam
Torres, Álvaro
Quintero, Enrique
Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
title Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
title_full Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
title_fullStr Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
title_full_unstemmed Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
title_short Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
title_sort immunogenicity and acceptance of influenza a (h1n1) vaccine in a cohort of chronic hepatitis c patients receiving pegylated-interferon treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493585/
https://www.ncbi.nlm.nih.gov/pubmed/23144908
http://dx.doi.org/10.1371/journal.pone.0048610
work_keys_str_mv AT hernandezguerramanuel immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT gonzalezmendezyanira immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT demolinapatricia immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT gimenogarciaantonioz immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT carrillomarta immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT casanovacarlos immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT pumarolatomas immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT jimenezalejandro immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT hernandezportomiriam immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT torresalvaro immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment
AT quinteroenrique immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment